-

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday, August 10, 2026 at 8:00 a.m. EDT.

Investor Webcast & Conference Call Information

Conference call link: https://register-conf.media-server.com/register/BI4a60039edc0640388f2ba0a6aab560e2

Webcast link: https://edge.media-server.com/mmc/p/q6mmpxd5

A replay of the webcast will be available on the Investors section of the Silence website at www.silence-therapeutics.com/events.

About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/.

Contacts

Inquiries:

Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
Tel: +1 (646) 637-3208
ir@silence-therapeutics.com

Industry:

Silence Therapeutics plc

NASDAQ:SLN
Details
Headquarters: London, United Kingdon
CEO: Craig Tooman
Employees: 120
Organization: PUB
Release Versions
English
$Cashtags
$SLN
Hashtags
#SenseofSilence

Contacts

Inquiries:

Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
Tel: +1 (646) 637-3208
ir@silence-therapeutics.com

Social Media Profiles
Silence Therapeutics Plc
More News From Silence Therapeutics plc

Silence Therapeutics to Participate in Three September Investor Conferences

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences and invited investors to participate by webcast. Cantor Global Healthcare Conference 2026 Fireside chat on Wednesday, September 9, 2026 at 10:55 a.m. ET H.C. Wainwright 28th Annual Global Investment Conference Fireside chat on Tuesday, September 15, 20...

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which inc...

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS. In addition, Silence...
Back to Newsroom